{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=RedHill+Biopharma+Limited",
    "query": {
      "sponsor": "RedHill Biopharma Limited"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=RedHill+Biopharma+Limited&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T17:19:40.908Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02757326",
      "title": "ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Opaganib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2016-12-13",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02757326"
    },
    {
      "nct_id": "NCT04616924",
      "title": "RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Mycobacterium Avium Complex Infection",
        "Bronchiectasis",
        "Lung Diseases"
      ],
      "interventions": [
        {
          "name": "RHB-204",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-12-01",
      "completion_date": "2023-08-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 25,
      "location_summary": "Glendale, California • Palm Springs, California • Farmington, Connecticut + 21 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04616924"
    },
    {
      "nct_id": "NCT01980095",
      "title": "ERADICATE Hp - Treating Helicobacter Pylori With RHB-105",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyspepsia",
        "Helicobacter Pylori Infection"
      ],
      "interventions": [
        {
          "name": "RHB-105",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 119,
      "start_date": "2013-11",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2019-09-24",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 12,
      "location_summary": "Anaheim, California • Chino, California • Jupiter, Florida + 8 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01980095"
    },
    {
      "nct_id": "NCT03009396",
      "title": "Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 54,
      "start_date": "2017-03-18",
      "completion_date": "2019-08-19",
      "has_results": true,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 6,
      "location_summary": "San Carlos, California • Marietta, Georgia • Topeka, Kansas + 3 more",
      "locations": [
        {
          "city": "San Carlos",
          "state": "California"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        },
        {
          "city": "Brockton",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03009396"
    },
    {
      "nct_id": "NCT03377179",
      "title": "A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma",
        "Cholangiocarcinoma Non-resectable",
        "Cholangiocarcinoma, Perihilar",
        "Cholangiocarcinoma, Extrahepatic",
        "Cholangiocarcinoma, Intrahepatic"
      ],
      "interventions": [
        {
          "name": "ABC294640",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine Sulfate 200 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2018-03-07",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2025-07-23",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03377179"
    },
    {
      "nct_id": "NCT04723537",
      "title": "Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Part A: Upamostat 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A: Upamostat 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A and B: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B: Upamostat 200 or 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2021-02-16",
      "completion_date": "2021-12-28",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 11,
      "location_summary": "Cutler Bay, Florida • Hialeah, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Cutler Bay",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "Bay City",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04723537"
    },
    {
      "nct_id": "NCT04467840",
      "title": "Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "Lung Infection"
      ],
      "interventions": [
        {
          "name": "Opaganib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 475,
      "start_date": "2020-08-21",
      "completion_date": "2021-07-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04467840"
    },
    {
      "nct_id": "NCT04414618",
      "title": "A Study of Opaganib in Coronavirus Disease 2019 Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Infections"
      ],
      "interventions": [
        {
          "name": "Opaganib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 42,
      "start_date": "2020-07-02",
      "completion_date": "2020-12-23",
      "has_results": true,
      "last_update_posted_date": "2022-03-21",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Miami, Florida • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04414618"
    },
    {
      "nct_id": "NCT05954286",
      "title": "PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Upamostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo (PO)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2024-01-29",
      "completion_date": "2025-04-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05954286"
    },
    {
      "nct_id": "NCT02229981",
      "title": "Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "Kaposi Sarcoma"
      ],
      "interventions": [
        {
          "name": "ABC294640",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-07",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-10-04T17:19:40.908Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02229981"
    }
  ]
}